Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Non-randomized, Open-label, Single-dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of BAY 1841788 (ODM-201) in Male Subjects With Hepatic Impairment, Renal Impairment and Normal Hepatic and Renal Function

NCT02894385 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT02894385
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02894385 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Non-randomized, Open-label, Single-dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of BAY 1841788 (ODM-201) in Male Subjects With Hepatic Impairment, Renal Impairment and Normal Hepatic and Renal Function
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Completed
Start date
September 13, 2016
Completion date
December 15, 2017
Enrollment
29 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic insufficiency, pharmacokinetics, renal insufficiency